Rocket Lab Stock’s Twelve-Month Gain Hides A Long Slide From Its High

Rocket Lab Stock's Twelve-Month Gain Hides A Long Slide From Its High

Rocket Lab's flight rate moved one way over the past year; its share price moved both ways.

Rocket Lab (RKLB) stock has returned 79.3% over the past twelve months, well ahead of the S&P 500's 20.5%, while the defense primes it gets grouped with did far less: LMT returned 31.6%, and NOC and LHX both finished lower. The awkward part is that the same twelve months hold a high of $150.23 against $72.95 now-a wild swing in valuation that far outpaced the fundamentals, even as trailing revenue surged 52.5% to $0.77 billion.

Twenty-Three Electron Flights, And Satellites Now Outweigh Launch

Days after this window opened, Rocket Lab flew its 70th Electron mission. On the day it closed, it flew its 93rd, lofting an Earth-imaging satellite for iQPS. Twenty-four flights in a year is the kind of track record management says is bringing customers to Neutron before it has flown. One of them is the Space Force, with a $397 million contract for Flatellite spacecraft that Neutron will carry. Satellites, not rockets, are now most of the revenue: Space Systems accounted for $189.5 million of the record $234 million in the second quarter of 2026, and backlog ended that quarter at $2.36 billion. Management has also agreed to buy Iridium, a constellation of 66 satellites that delivered more than $870 million of revenue over the past year. That is more than the $0.77 billion Rocket Lab booked over its own trailing twelve months, though the CEO acknowledges Iridium grows slowly.

Neutron Is What The Price Is Really Buying

None of that carries a $45.9 billion market value on $0.77 billion of trailing revenue, about 60 times sales. That multiple does not pick up Iridium until the deal closes, which management expects in mid-2027. In the gap sits Neutron, the medium-lift rocket Rocket Lab has been building toward for years and has still not launched. Production lines up with target delivery to the pad in the fourth quarter of 2026, and the CEO says the window for a launch before the end of 2026 is narrowing while the team trades first-flight timing against how fast it can reach a tenth launch. The bill shows up in cash: non-GAAP free cash flow was a use of $110.1 million in the second quarter of 2026 versus $77.4 million in the first, and the CFO expects it to stay elevated in the third quarter of 2026, against roughly $2.4 billion of cash at quarter end that management intends in part for the Iridium payment. Waiting on one launch for the cash-flow turn is a different proposition from the Trefis High Quality Portfolio, which holds businesses that already generate cash.

The Stand-Alone Clock Starts On A Flight Nobody Has Seen

The CFO says that on a stand-alone Rocket Lab basis, adjusted EBITDA turns positive in the quarter after a successful first Neutron test flight, and that cash generation follows roughly 18 to 24 months later, because the company must keep building a fleet of Neutron tails in between. So the twelve-month gain is not the market discovering this business: the flight rate moved one way all year. What is still unsettled is the launch date everything else is timed off. That, not the next contract announcement, is the variable to watch. If you want to see what today's price already embeds, the market-implied growth screen sizes it.

A Timeline You Do Not Control Is Still A Bet

Rocket Lab may well fly Neutron, close Iridium and grow into the price. But a portfolio built on rules does not need any single launch to go right, which is the difference between compounding on a system and waiting on a date. That portfolio has a track record of outpacing the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000.